Aktiverede T-celler i tumorer dræber andre cancerceller

Aktiverede T-celler i tumorer dræber andre cancerceller

Interessant studie hvor forskere fra Stanford University School of Medicine forsøger at injicere to immunstimulerende stoffer i tumorer på mus, hvorefter der elimineres kræft i kroppen selv andre steder i kroppen end tumoren. Der aktiveres T-celler i tumoren og nogle af dem forlader tumoren og går på jagt efter andre cancerceller i kroppen og dræber dem. I dette forsøg fik 87 ud af 90 mus kureret deres kræft.

Cancer ‘vaccine’ eliminates tumors in mice
Activating T cells in tumors eliminated even distant metastases in mice, Stanford researchers found. Lymphoma patients are being recruited to test the technique in a clinical trial.
Stanford Medicine 31. januar 2018 

Selve studiet kan findes her:


It has recently become apparent that the immune system can cure cancer. 
In some of these strategies, the antigen targets are preidentified and 
therapies are custom-made against these targets. In others, antibodies 
are used to remove the brakes of the immune system, allowing 
preexisting T cells to attack cancer cells. We have used another 
noncustomized approach called in situ vaccination. Immunoenhancing 
agents are injected locally into one site of tumor, thereby triggering 
a T cell immune response locally that then attacks cancer throughout 
the body. We have used a screening strategy in which the same syngeneic 
tumor is implanted at two separate sites in the body. One tumor is then 
injected with the test agents, and the resulting immune response is 
detected by the regression of the distant, untreated tumor. Using this 
assay, the combination of unmethylated CG–enriched oligodeoxynucleotide 
(CpG)—a Toll-like receptor 9 (TLR9) ligand—and anti-OX40 antibody 
provided the most impressive results. TLRs are components of the innate 
immune system that recognize molecular patterns on pathogens. Low doses 
of CpG injected into a tumor induce the expression of OX40 on CD4+ T 
cells in the microenvironment in mouse or human tumors. An agonistic 
anti-OX40 antibody can then trigger a T cell immune response, which is 
specific to the antigens of the injected tumor. Remarkably, this 
combination of a TLR ligand and an anti-OX40 antibody can cure multiple 
types of cancer and prevent spontaneous genetically driven cancers.
Science Translational Medicine  31 Jan 2018

#forskning #ToRead #cancer

Skriv en kommentar